公开(公告)号：HU0101959A2

公开(公告)日：2001-09-28

申请号：HU0101959

申请日：1999-03-05

Applicant: ABBOTT LAB

Inventor： ABAD-ZAPATERO CELERINO ,  GREER JONATHAN ,  NIENABER VICKI L ,  NORBECK DANIEL W

IPC: G01N33/50 ,  G01N23/20 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/00

公开(公告)号：NO20004860A

公开(公告)日：2000-11-24

申请号：NO20004860

申请日：2000-09-27

Applicant: ABBOTT LAB

Inventor： SAUER DARYL R ,  HAVIV FORTUNA ,  RANDOLPH JOHN ,  MORT NICHOLAS A ,  DALTON CHRISTOPHER ROBIN ,  BRUNCKO MILAN ,  KAMINSKI MICHELE A ,  CRAWFORD BRADLEY W ,  FREY LISA MARIE ,  GREER JONATHAN

IPC: A61K31/7042 ,  A61K31/7048 ,  A61K31/7056 ,  A61P5/24 ,  A61P13/08 ,  A61P15/00 ,  A61P35/00 ,  A61P43/00 ,  C07H17/08

CPC classification number: C07H17/08

公开(公告)号：CA2351187A1

公开(公告)日：2000-05-25

申请号：CA2351187

申请日：1999-11-09

Applicant: ABBOTT LAB

Inventor： CRAWFORD BRADLEY W ,  HAVIV FORTUNA ,  SWENSON ROLF E ,  BRUNCKO MILAN ,  KAMINSKI MICHELE A ,  DWIGHT WESLEY J ,  FREY LISA M ,  DEMATTEI JOHN ,  GREER JONATHAN

IPC: C07D217/06 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/4741 ,  A61K31/55 ,  A61P5/00 ,  A61P13/08 ,  A61P15/00 ,  A61P35/00 ,  C07D217/04 ,  C07D217/14 ,  C07D217/16 ,  C07D217/18 ,  C07D217/20 ,  C07D217/22 ,  C07D217/26 ,  C07D223/16 ,  C07D401/04 ,  C07D401/06 ,  C07D401/08 ,  C07D401/12 ,  C07D491/04 ,  C07D491/056 ,  C07D221/00 ,  C07D317/00 ,  C07D319/00 ,  C07D401/10

Abstract: Tetrahydroisoquinoline derivatives of formula (I): or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.

公开(公告)号：CA2321968A1

公开(公告)日：1999-09-10

申请号：CA2321968

申请日：1999-03-05

Applicant: ABBOTT LAB

Inventor： NORBECK DANIEL W ,  ABAD-ZAPATERO CELERINO ,  GREER JONATHAN ,  NIENABER VICKI L

IPC: G01N33/50 ,  G01N23/20 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  C30B7/00

Abstract: X-ray crystallography can be used to screen compounds that are not known ligands of a target biomolecule for their ability to bind the target biomolecule. The method includes obtaining a crystal of a target biomolecule; exposing the target biomolecule crytal to one or more test samples; and obtaining an X-ray crystal diffraction pattern to determine whether a ligand/receptor complex is formed. The target is exposed to the test samples by either co-crystallizing a biomolecule in the presence of one or more test samples or soaking the biomolecule crystal in a solution of one or more test samples. In another embodiment, structural information from ligand/receptor complexes are used to design ligands that bind tighter, that bind more specifically, that have better biological activity or that have better safety profile. A further embodiment of the invention comprises identifying or designing biologically-active moieties by the instant process. In a further embodiment, a biomolecule crystal having an easily accessible active site is formed by co-crystallizing the biomolecule with a degradable ligand and degrading the ligand.

公开(公告)号：CA2136078A1

公开(公告)日：1994-06-23

申请号：CA2136078

申请日：1993-11-30

Applicant: ABBOTT LAB

Inventor： GREER JONATHAN ,  HAVIV FORTUNA ,  FITZPATRICK TIMOTHY D ,  SWENSON ROLF E ,  NICHOLS CHARLES J ,  MORT NICHOLAS A

IPC: A61K38/04 ,  A61K38/00 ,  A61P5/00 ,  C07K7/23 ,  A61K38/09

Abstract: 2136078 9413313 PCTABS00032 The present invention provides a class of decapeptide compounds which are potent antagonists of LHRH activity and which have the structure A1-D2-E3-G4-J5-L6-M7-Q8-R9-T10. The compounds of the percent invention are characterized by having an .OMEGA.-amino-functionalized side chain on the D-aminoacyl residue at position 6. The .OMEGA.-amino group of this side chain is further derivatized by the attachment of an extending group which likewise has a terminal amino group which is capped by an acyl group.

公开(公告)号：NO903454A

公开(公告)日：1991-02-08

申请号：NO903454

申请日：1990-08-06

Applicant: ABBOTT LAB

Inventor： HAVIV FORTUNA ,  GREER JONATHAN ,  PALABRICA CHRISTOPHER A ,  FITZPATRICK TIMOTHY D

IPC: A61K38/04 ,  A61K38/00 ,  A61P5/00 ,  C07K1/06 ,  C07K7/23 ,  C07K14/575 ,  C07K7/06

CPC classification number: C07K7/23 ,  A61K38/00

公开(公告)号：AU767991B2

公开(公告)日：2003-11-27

申请号：AU2987899

申请日：1999-03-05

Applicant: ABBOTT LAB

Inventor： NIENABER VICKI L ,  GREER JONATHAN ,  ABAD-ZAPATERO CELERINO ,  NORBECK DANIEL W

IPC: G01N33/50 ,  G01N23/20 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/00

公开(公告)号：TR200101127T2

公开(公告)日：2002-06-21

申请号：TR200101127

申请日：1999-03-05

Applicant: ABBOTT LAB

Inventor： NIENABER VICKI L ,  GREER JONATHAN ,  ABAD-ZAPATERO CELERINO ,  NORBECK DANIEL W

IPC: G01N33/50 ,  G01N23/20 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/00

公开(公告)号：DE69330838T2

公开(公告)日：2002-04-25

申请号：DE69330838

申请日：1993-12-14

Applicant: ABBOTT LAB

Inventor： HAVIV FORTUNA ,  GREER JONATHAN ,  SWENSON ROLF E ,  SAUER DARYL R

IPC: A61K38/04 ,  A61K38/00 ,  A61P15/00 ,  C07K7/06 ,  C07K7/23 ,  A61K38/09 ,  A61K38/24

Abstract: A class of potent LHRH decapeptide antagonists possess N-alkylated aminoacyl residues where the side-chain portion of the residue is a 4-(substimtedamino)phenylalanyl, 4-(substituted-amino)cyclohexylalanyl, or OMEGA -(substitutedamino)alkyl group, and additionally the aminoacyl residues at position 5 are N-alkylated on the nitrogen atom of the peptide backbone.

公开(公告)号：TR200101200T2

公开(公告)日：2002-02-21

申请号：TR200101200

申请日：1999-03-05

Applicant: ABBOTT LAB

Inventor： NIENABER VICKI L ,  GREER JONATHAN ,  ABAD-ZAPATERO CELERINO ,  NORBECK DANIEL W

IPC: G01N33/50 ,  G01N23/20 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/00